Biotech News
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor "What This Means" Segment
Access the "What This Means" segment here
LA JOLLA, CA, Feb. 17, 2026 ...
Open original release
Related news
GRIGRI Bio2026-05-14 08:35 EST
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
GRIGRI Bio2026-06-18 13:31 EST
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
GRI Bio
BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.
Recent company news
GRIGRI Bio2026-06-18 13:31 EST
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
GRIGRI Bio2026-05-14 08:35 EST
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
GRIGRI Bio2026-04-08 08:30 EST
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
GRIGRI Bio2026-02-17 09:15 EST
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor "What This Means" Segment
GRIGRI Bio2026-02-05 09:15 EST
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Stock data
- Close
- 1.40 USD
- Market cap
- 3.56M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States